<DOC>
	<DOC>NCT02146378</DOC>
	<brief_summary>The purpose of this study is to understand safety (e.g., occurrence of adverse drug reactions [ADRs]) and efficacy data on the long-term use of Vyndaqel Capsules (hereinafter referred to as Vyndaqel) in all patients who received this drug under actual use conditions after its marketing.</brief_summary>
	<brief_title>Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>Both prospective and retrospective is acceptable All the patients whom an investigator prescribes Vyndaqel should be registered</detailed_description>
	<criteria>The subjects of this surveillance are all patients who received Vyndaqel. Patients not receive Vyndaqel.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>